BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34272849)

  • 21. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
    Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.
    Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Röhrich S; Saenger P; Horikawa R
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2569-2578. PubMed ID: 36995872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced Effectiveness and Comparable Safety in Biweekly
    Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
    Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lonapegsomatropin: Pediatric First Approval.
    Lamb YN
    Paediatr Drugs; 2022 Jan; 24(1):83-90. PubMed ID: 34709591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency.
    Loftus J; Miller BS; Parzynski CS; Alvir J; Chen Y; Jhingran P; Gupta A; DeKoven M; Divino V; Tse J; He J; Wajnrajch M
    Endocr Pract; 2022 Jun; 28(6):565-571. PubMed ID: 35263660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.
    Garner T; Clayton P; Højby M; Murray P; Stevens A
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1214-1221. PubMed ID: 38066644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
    Luo X; Hou L; Liang L; Dong G; Shen S; Zhao Z; Gong CX; Li Y; Du ML; Su Z; Du H; Yan C
    Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to growth hormone therapy guidelines in a real-world French cohort of adult patients with growth hormone deficiency.
    Borson-Chazot F; Chabre O; Salenave S; Klein M; Brac de la Perriere A; Reznik Y; Kerlan V; Hacques E; Villette B
    Ann Endocrinol (Paris); 2021 Feb; 82(1):59-68. PubMed ID: 33290752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GH deficiency status combined with GH receptor polymorphism affects response to GH in children.
    Valsesia A; Chatelain P; Stevens A; Peterkova VA; Belgorosky A; Maghnie M; Antoniazzi F; Koledova E; Wojcik J; Farmer P; Destenaves B; Clayton P;
    Eur J Endocrinol; 2015 Dec; 173(6):777-89. PubMed ID: 26340968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
    Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency.
    Liang Y; Zhang C; Wei H; Du H; Zhang G; Yang Y; Zhang H; Gong H; Li P; Song F; Xu Z; He R; Zhou W; Zheng H; Sun L; Luo X
    Front Endocrinol (Lausanne); 2022; 13():922304. PubMed ID: 36034448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
    Romer T; Peter F; Saenger P; Starzyk J; Koehler B; Korman E; Walczak M; Wasik R; Ginalska-Malinowska M; Solyom E; Berghout A
    J Endocrinol Invest; 2007; 30(7):578-89. PubMed ID: 17848841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial.
    Czepielewski MA; Garret Q; Vencio SAC; Rassi N; Felicio JS; Faria MS; Senn CCP; Bronstein MD; Cerqueira MJAG; Neves ACL; Sgarbi JA; Spinola-Castro AM; Cunha MPR; Bandeira F; Toffoletto O; Afiune J; Baradelli R; Rodrigues DG; Scharf M
    Growth Horm IGF Res; 2019; 48-49():29-35. PubMed ID: 31493626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children.
    Hou L; Liang Y; Wu W; Lin HH; Luo XP; Ying YQ
    Growth Horm IGF Res; 2020; 53-54():101331. PubMed ID: 32777706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly Growth Hormone (Lonapegsomatropin) Causes Severe Transient Hyperglycemia in a Child with Obesity.
    Alkhatib EH; Dauber A; Estrada DE; Majidi S
    Horm Res Paediatr; 2023; 96(5):542-546. PubMed ID: 37015214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: results of the Easypod™ connect observational study (ECOS).
    Blanco-López A; Antillón-Ferreira C; Saavedra-Castillo E; Barrientos-Pérez M; Rivero-Escalante H; Flores-Caloca O; Calzada-León R; Rosas-Guerra CC; Koledova E; Chiquete E; Ayala-Estrada A
    J Endocrinol Invest; 2020 Oct; 43(10):1447-1452. PubMed ID: 32239476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
    Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
    Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
    J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study.
    Maniatis AK; Carakushansky M; Galcheva S; Prakasam G; Fox LA; Dankovcikova A; Loftus J; Palladino AA; de Los Angeles Resa M; Turich Taylor C; Dattani MT; Lebl J
    J Endocr Soc; 2022 Oct; 6(10):bvac117. PubMed ID: 36101713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone?
    Colmenares A; González L; Gunczler P; Lanes R
    J Pediatr Endocrinol Metab; 2012; 25(7-8):651-7. PubMed ID: 23155689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.